A First-in-Human Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169, a CD38-targeting Engineered Toxin Body (ETB), in Relapsed or Refractory Multiple Myeloma
AMERICAN JOURNAL OF HEMATOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要